NCT05503134View on ClinicalTrials.gov

Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

Universal Donor Natural Killer Cells

Six doses of UD-NK cells will be given thrice weekly for two weeks for up to 2 cycles of treatment

Trial Locations (1)

43205

RECRUITING

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Nationwide Children's Hospital

OTHER